Linezolid for Drug-Resistant Tuberculosis

N Engl J Med. 2022 Sep 1;387(9):842-843. doi: 10.1056/NEJMe2208554.

Authors

Guy Thwaites¹, Nhung V Nguyen¹

Affiliation

¹ From the Oxford University Clinical Research Unit, Ho Chi Minh City (G.T.), and the National Lung Hospital and the Vietnam National Tuberculosis Program, Hanoi (N.V.N.) - all in Vietnam; and the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (G.T.).

PMID: 36053511
DOI: 10.1056/NEJMe2208554

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antitubercular Agents / therapeutic use
Extensively Drug-Resistant Tuberculosis* / drug therapy
Humans
Linezolid / therapeutic use
Mycobacterium tuberculosis*
Treatment Outcome
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents
Linezolid